首页> 外文会议>International Symposium on Industrial Crystallization >Ultrasound a versatile process analytical tool for quantitative in-line monitoring of pharmaceutical oral/injection formulations
【24h】

Ultrasound a versatile process analytical tool for quantitative in-line monitoring of pharmaceutical oral/injection formulations

机译:超声波化多功能工艺分析工具,用于定量在线监测药物/注射配方

获取原文

摘要

The pharmaceutical industry follows the quality-by-design approach of the Food and Drug Administration (FDA) that includes the application of process analytical technology (PAT) to guarantee among other the required product quality of drug formulations [1]. Therefore, a variety of methods for the quantification of pharmaceutical formulations have been intensively discussed in recent years [2-5]. These studies have addressed the application of inline PATs, such as NIR, RAMAN, ultrasound spectroscopy. Further studies have assessed the application of FTIR, FBRM, UV, turbidity, or conductivity to measure solution and suspension properties [6-8]. All PATs provide the possibility to monitor process parameters in real time, which leads to more constant product quality by real-time process decision making and process adjustments. However, most of the aforementioned PATs are limited to measuring either solid or liquid phase. Moreover, there are obstacles with electrically non-conducting, dense, concentrated, or optically opaque solutions [9]. Here, the ultrasound-based technologies have clear advantages, because most materials are ultrasonically transparent and hence allow the analysis of a broad variety of sample types (solution, suspension, lotion, emulsion) [2,3,9]. Recent studies have pioneered the use of ultrasound spectroscopy in quantification of drug concentration in different types of formulations [2-4]. However, to the best of our knowledge real-time monitoring of drug concentration in oral/injection pharmaceutical formulations (liquid/suspension) has never been assessed by means of single-frequency ultrasound (US). The aim of this study is to evaluate the application of US as a robust, cost-effective, and small-scale PAT (including control box) to determine and monitor the concentration of commercial, oral/injection pharmaceutical formulations, both solutions and suspensions. The quality and versatility of US are assessed by comparing the results with the outcome of established PATs able to measure solution concentration (conductivity, UV-vis, FlowIR) as well as suspension concentration (FBRM, turbidity) which are relatively small in size (including control box). The latter is important if the PAT should be utilized in small-scale applications with critical space limitations.
机译:制药工业如下来保证之间药物制剂[1]的其它所要求的产品质量的食品和药物管理局(FDA),其包括过程分析技术(PAT)的应用程序的质量按设计方法。因此,各种各样的用于药物制剂的定量方法进行了深入近年来[2-5]中讨论。这些研究已经解决了内联PATS,如NIR,拉曼光谱学超声的应用。进一步的研究已经评估FTIR,FBRM,UV,浊度,或电导率的应用以测量溶液和悬浮性质[6-8]。所有PATS提供实时监控过程参数,可能导致更稳定的产品质量进行实时处理决策和工艺调整。然而,大多数前述PATS被限于测量固体或液体相。此外,存在与不导电的,致密的障碍,浓缩,或不透光的解决方案[9]。在此,基于超声的技术有明显的优点,因为大多数材料是超声透明,并因此允许的各种各样的样品类型(溶液,悬浮液,洗剂,乳液)[2,3,9]的分析。最近的研究已经开创了不同类型的制剂[2-4]中的药物浓度的定量使用超声光谱学。然而,尽我们所知的实时监测口服/注射药物制剂的药物浓度(液/悬浮液)从未通过单频超声(US)来评估。本研究的目的是评估美国的应用程序作为一个健壮的,具有成本效益,和小规模PAT(包括控制盒),以确定和监测商业,口服/注射的药物制剂,这两种溶液和悬浮液的浓度。美国的质量和通用性是通过将结果与既定PATS的能够测量溶液浓度(导电率,UV-VIS,FlowIR)以及悬浮浓度(FBRM,浊度),其是相对小的尺寸的结果进行比较(包括评估控制箱)。后者是重要的,如果在PAT应与临界空间限制的小规模应用中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号